Full Press Release Details
Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process
data collected from the usage and experience of the medical professionals in the formative study will be used to support the Company's
anticipated milestones
Mass., May 31, 2023 - Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic Surgical System,
the first single-use endovascular surgical robotic system, announces that an additional milestone was achieved when medical professionals
experienced the Company's LIBERTY Robotic Surgical System as part of a formative study. The study was designed to enable medical
professionals, including physicians and Cath-lab technicians, to use and experience LIBERTY in a real-use simulated environment.
study was performed and managed by experts from a company specializing in conducting Human Factors and Usability Engineering tests of
study included five teams, each consisting of an interventional radiologist and a Cath-Lab technician and simulated the expected clinical
setup and use of the LIBERTY Robotic Surgical System. All participants were successfully trained on the system prior
to their participation and the study validated that the LIBERTY Robotic Surgical System operation and setup are intuitive.
and data from the study exhibited high subjective grading both by the physicians and the technicians, with no comments made on the designed
and establishing close relationships with our target audience, enables the Company to gain valuable feedback and increase awareness to
our unique system. In parallel to our regulatory and pre-clinical efforts, we invest in receiving endorsements from leading experts and
institutes which we believe will allow us to leverage our path to the clinical stages and later on to the market," commented Eyal
Morag, Chief Medical Officer.
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within
LIBERTY Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today,
by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain.
The Company believes the LIBERTY Robotic Surgical System's remote operation has the potential to be the first system
to democratize endovascular interventional procedures.
information about Microbot Medical is available at http://www.microbotmedical.com.
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates," "expects"
and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of LIBERTY ,
the outcome of its studies to evaluate LIBERTY , whether the Company's core business focus program and cost reduction
plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while it seeks additional working capital, any
failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could
adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory
approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual
property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in
Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's
web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required